NERM
UTHR icon

New England Research & Management’s United Therapeutics UTHR Stock Holding History

New England Research & Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$910K Buy
1,680
+550
+49% +$310K 0.35% 76
2026
Q1 		$670K Sell
1,130
-3,310
-75% -$1.65M 0.28% 93
2025
Q4 		$2.16M Hold
4,440
– – 0.95% 35
2025
Q3 		$1.86M Sell
4,440
-1,085
-20% -$365K 0.85% 35
2025
Q2 		$1.59M Sell
5,525
-125
-2% -$37.4K 0.75% 40
2025
Q1 		$1.74M Buy
5,650
+10
+0.2% +$3.43K 0.88% 34
2024
Q4 		$1.99M Sell
5,640
-2,080
-27% -$765K 1.01% 28
2024
Q3 		$2.77M Sell
7,720
-475
-6% -$160K 1.3% 17
2024
Q2 		$2.61M Sell
8,195
-2,235
-21% -$592K 1.25% 16
2024
Q1 		$2.4M Buy
10,430
+2,395
+30% +$540K 1.18% 24
2023
Q4 		$1.77M Sell
8,035
-470
-6% -$108K 0.94% 31
2023
Q3 		$1.92M Buy
8,505
+2,225
+35% +$512K 1.09% 24
2023
Q2 		$1.39M Buy
6,280
+715
+13% +$158K 0.8% 48
2023
Q1 		$1.25M Buy
5,565
+1,115
+25% +$275K 0.73% 49
2022
Q4 		$1.24M Sell
4,450
-1,100
-20% -$278K 0.71% 46
2022
Q3 		$1.16M Buy
+5,550
New +$1.24M 0.73% 45
2022
Q1 		– Sell
-4,675
Closed -$1.01M – 197
2021
Q4 		$1.01M Sell
4,675
-775
-14% -$152K 0.49% 66
2021
Q3 		$1.01M Buy
5,450
+4,325
+384% +$852K 0.53% 67
2021
Q2 		$202K Sell
1,125
-2,125
-65% -$405K 0.1% 169
2021
Q1 		$544K Buy
+3,250
New +$542K 0.3% 101

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

New England Research & Management's UTHR Position: Q2 2026 in Review

New England Research & Management increased its United Therapeutics (UTHR) stake by 49% in Q2 2026, buying an estimated $310K and bringing the position to 1,680 shares worth $910K. The position accounts for 0.35% of the portfolio, ranked #76.

New England Research & Management first reported a position in UTHR in Q1 2021 and has held it in 20 quarters since. The position peaked at $2.77M in Q3 2024. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • New England Research & Management held 1,680 shares of United Therapeutics worth $910K as of Q2 2026.
  • New England Research & Management bought 550 United Therapeutics shares in Q2 2026, an estimated $310K.
  • United Therapeutics made up 0.35% of New England Research & Management's portfolio in Q2 2026, its #76 holding.
  • New England Research & Management first reported a position in United Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • New England Research & Management's United Therapeutics position peaked at $2.77M in Q3 2024.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on New England Research & Management's 13F filing for Q2 2026, filed 9 Jul 2026.